ABG
CSTL icon

Ally Bridge Group’s Castle Biosciences CSTL Stock Holding History

Ally Bridge Group’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-100,000
Closed -$6.85M – 30
2021
Q1 		$6.85M Sell
100,000
-110,000
-52% -$8.27M 1.31% 23
2020
Q4 		$14.1M Buy
+210,000
New +$11.4M 2.42% 12

Other funds holding CSTL

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ZCI
Zevenbergen Capital Investments Edmonds, Washington $4.38B AUM 56.68% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PM
Pembroke Management Montreal, Quebec, Canada $691M AUM 27.96% 1-Year Est. Return

Ally Bridge Group's CSTL Position: Q2 2021 in Review

Ally Bridge Group sold out of Castle Biosciences (CSTL) in Q2 2021, closing a stake of 100,000 shares — an estimated $6.85M sold.

Ally Bridge Group first reported a position in CSTL in Q4 2020 and held it in 2 quarters. The position peaked at $14.1M in Q4 2020. 181 funds tracked by Wall St. Rank hold CSTL as of Q2 2021.

  • Ally Bridge Group reported no remaining Castle Biosciences position as of Q2 2021 after selling out during the quarter.
  • Ally Bridge Group sold 100,000 Castle Biosciences shares in Q2 2021, an estimated $6.85M.
  • Ally Bridge Group first reported a position in Castle Biosciences in Q4 2020 and held it in 2 quarters.
  • Ally Bridge Group's Castle Biosciences position peaked at $14.1M in Q4 2020.
  • 181 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2021.

Based on Ally Bridge Group's 13F filing for Q2 2021, filed 16 Aug 2021.